Terms: = Pancreatic cancer AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2 AND Treatment
12 results:
1. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors in pancreatic cancer.
Lin Q; Serratore A; Perri J; Roy Chaudhuri T; Qu J; Ma WW; Kandel ES; Straubinger RM
Br J Pharmacol; 2024 May; 181(9):1383-1403. PubMed ID: 37994108
[TBL] [Abstract] [Full Text] [Related]
2. Integrated Workflow for the Label-Free Isolation and Genomic Analysis of Single Circulating Tumor Cells in pancreatic cancer.
Rupp B; Owen S; Ball H; Smith KJ; Gunchick V; Keller ET; Sahai V; Nagrath S
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887203
[TBL] [Abstract] [Full Text] [Related]
3. Anticancer drug resistance: An update and perspective.
Nussinov R; Tsai CJ; Jang H
Drug Resist Updat; 2021 Dec; 59():100796. PubMed ID: 34953682
[TBL] [Abstract] [Full Text] [Related]
4. Novel insights into immunohistochemical analysis for diagnosing serous neoplasm of the pancreas: aquaporin 1, stereocilin, and transmembrane protein 255B.
Watase C; Fuse M; Ino Y; Naito C; Hiraoka N
Histopathology; 2021 Nov; 79(5):872-879. PubMed ID: 34288030
[TBL] [Abstract] [Full Text] [Related]
5. Indirect cholinergic activation slows down pancreatic cancer growth and tumor-associated inflammation.
Pfitzinger PL; Fangmann L; Wang K; Demir E; Gürlevik E; Fleischmann-Mundt B; Brooks J; D'Haese JG; Teller S; Hecker A; Jesinghaus M; Jäger C; Ren L; Istvanffy R; Kühnel F; Friess H; Ceyhan GO; Demir IE
J Exp Clin Cancer Res; 2020 Dec; 39(1):289. PubMed ID: 33357230
[TBL] [Abstract] [Full Text] [Related]
6. Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, fgfr3 and TATI in Bladder cancers.
Matuszczak M; Salagierski M
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397531
[TBL] [Abstract] [Full Text] [Related]
7. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors.
Siemers NO; Holloway JL; Chang H; Chasalow SD; Ross-MacDonald PB; Voliva CF; Szustakowski JD
PLoS One; 2017; 12(7):e0179726. PubMed ID: 28749946
[TBL] [Abstract] [Full Text] [Related]
8. Cholinergic receptors as target for cancer therapy in a systems medicine perspective.
Russo P; Del Bufalo A; Milic M; Salinaro G; Fini M; Cesario A
Curr Mol Med; 2014; 14(9):1126-38. PubMed ID: 25324001
[TBL] [Abstract] [Full Text] [Related]
9. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract] [Full Text] [Related]
10. Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival.
Oberic L; Viret F; Baey C; Ychou M; Bennouna J; Adenis A; Peiffert D; Mornex F; Pignon JP; Celier P; Berille J; Ducreux M
Radiat Oncol; 2011 Sep; 6():124. PubMed ID: 21943032
[TBL] [Abstract] [Full Text] [Related]
11. [S-1+gemcitabine (GEM) therapy was effective in a case of unresectable pancreatic head carcinoma].
Takada J; Okuda K; Kenno S; Shimada S; Oba G; Shimokuni T; Aoki T; Hamada H
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2120-2. PubMed ID: 19106543
[TBL] [Abstract] [Full Text] [Related]
12. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer.
Leung HY; Gullick WJ; Lemoine NR
Int J Cancer; 1994 Dec; 59(5):667-75. PubMed ID: 7960240
[TBL] [Abstract] [Full Text] [Related]
